Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males (RIGHT)
Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive Fulvestrant 250 mg intramuscularly or anastrozole 1 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern Memorial Hospital
-
接触:
- Nancy Ly, MD
- 电话号码:2624551560
- 邮箱:nancy.ly@nm.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male sex
- Age ≥ 50 years at time of enrollment
- Symptomatic unilateral inguinal hernia confirmed on physical examination
- Hernia visible / confirmed on groin ultrasound
- Non-recurrent inguinal hernia (primary hernia only)
- Willing and able to provide written informed consent
- Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up
- Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose
- Willing to be counseled regarding vitamin D and calcium supplementation
Exclusion Criteria:
Hernia Characteristics
- Scrotal hernia (any)
- Bilateral inguinal hernia
- Recurrent inguinal hernia (prior repair at same site)
Renal & Hepatic
- Clinically significant renal dysfunction judged by investigator to increase study risk
- Clinically significant hepatic dysfunction at baseline
Hematologic
■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia)
Urologic / Prostate
- Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment
- Clinically significant untreated prostate disease
Skeletal / Bone
- Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site)
- Recent fragility fracture (within prior 12 months or as judged by investigator)
- Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression
Immunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens)
Psychiatric
■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation
Reproductive / Fertility ■ Actively pursuing fertility or planning conception during study participation
Prior / Concomitant Therapy
- Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation
- Prior or current use of aromatase inhibitor or selective estrogen receptor modulator / degrader within 6 months of enrollment
- Active malignancy under treatment
General
■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Anastrozole 1 mg
Participants will receive anastrozole 1 mg orally once daily for 6 months. |
Participants will receive anastrozole 1 mg orally once daily for 6 months. |
|
实验性的:Fulvestrant 250 mg
Participants will receive fulvestrant 250 mg intramuscularly monthly for 6 doses, given at the baseline visit and at Months 1 through 5. |
Participants will receive fulvestrant 250 mg intramuscularly on Days 1 and 29, then monthly for 6 months. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite Safety Event Rate
大体时间:6 months
|
Proportion of participants experiencing a composite safety event, defined as hernia-related complications including incarceration, strangulation, or emergent surgery; drug-related toxicity Grade 2 or higher by CTCAE v5.0; or procedure/treatment-related events Clavien-Dindo Grade III or higher. |
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum Estradiol Level
大体时间:Baseline to 6 months
|
Change in Serum Estradiol Level |
Baseline to 6 months
|
|
Serum Testosterone Level
大体时间:Baseline to 6 months
|
Change in Serum Testosterone Level |
Baseline to 6 months
|
|
Serum LH Level
大体时间:Baseline to 6 months
|
Change in Serum LH Level |
Baseline to 6 months
|
|
Serum FSH Level
大体时间:Baseline to 6 months
|
Change in Serum FSH Level |
Baseline to 6 months
|
|
Hernia Size on Ultrasound
大体时间:Baseline to 6 months; baseline to 1 year
|
Change in Hernia Size on Ultrasound |
Baseline to 6 months; baseline to 1 year
|
|
European Registry for Abdominal Wall Hernias Quality of Life (EuraHS-QoL) Score
大体时间:Baseline to 6 months; baseline to 1 year
|
The EuraHS-QoL questionnaire assesses pain, activity restriction, and cosmetic discomfort related to abdominal wall hernias. Scores range from 0 to 90, with higher scores indicating worse hernia-related quality of life and symptom burden. |
Baseline to 6 months; baseline to 1 year
|
|
Euro Quality of Life 5 Dimension 5 Level (EQ-5D-5L) Score
大体时间:Baseline to 6 months; baseline to 1 year
|
EQ-5D-5L index value, where 1 indicates full health and 0 indicates a state equivalent to death; values below 0 are possible. Higher scores indicate better health-related quality of life. EQ VAS self-rated health is scored from 0 (worst) to 100 (best imaginable health). |
Baseline to 6 months; baseline to 1 year
|
|
Bone Mineral Density on DEXA
大体时间:Baseline, 3 months, and 1 year
|
Change in Bone Mineral Density on DEXA |
Baseline, 3 months, and 1 year
|
|
Hernia Type on CT
大体时间:Baseline
|
Characterization of the inguinal hernia on non-contrast CT of the pelvis. |
Baseline
|
|
AUA International Prostate Symptom Score (IPSS)
大体时间:Baseline to 1 year
|
Seven-item questionnaire of urinary symptoms. Total score ranges from 0 to 35; higher scores indicate more severe symptoms. |
Baseline to 1 year
|
|
PROMIS Sexual Function and Satisfaction
大体时间:Baseline to 1 year
|
PROMIS Sexual Function and Satisfaction domain scores, reported as T-scores (mean 50, SD 10 in the U.S. reference population). |
Baseline to 1 year
|
合作者和调查者
出版物和有用的链接
一般刊物
- HerniaSurge Group. International guidelines for groin hernia management. Hernia. 2018 Feb;22(1):1-165. doi: 10.1007/s10029-017-1668-x. Epub 2018 Jan 12.
- Potluri T, You T, Yin P, Coon J 5th, Stulberg JJ, Dai Y, Escobar DJ, Lieber RL, Zhao H, Bulun SE. Estrogen receptor-alpha ablation reverses muscle fibrosis and inguinal hernias. J Clin Invest. 2025 Feb 4;135(6):e179137. doi: 10.1172/JCI179137.
- Zhao H, Zhou L, Li L, Coon V J, Chatterton RT, Brooks DC, Jiang E, Liu L, Xu X, Dong Z, DeMayo FJ, Stulberg JJ, Tourtellotte WG, Bulun SE. Shift from androgen to estrogen action causes abdominal muscle fibrosis, atrophy, and inguinal hernia in a transgenic male mouse model. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10427-E10436. doi: 10.1073/pnas.1807765115. Epub 2018 Oct 16.
- Matthews RD, Neumayer L. Inguinal hernia in the 21st century: an evidence-based review. Curr Probl Surg. 2008 Apr;45(4):261-312. doi: 10.1067/j.cpsurg.2008.01.002. No abstract available.
- Potluri T, Taylor MJ, Stulberg JJ, Lieber RL, Zhao H, Bulun SE. An estrogen-sensitive fibroblast population drives abdominal muscle fibrosis in an inguinal hernia mouse model. JCI Insight. 2022 Apr 19;7(9):e152011. doi: 10.1172/jci.insight.152011.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 00225501
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared outside the study team. Aggregate study results may be disseminated through presentations and publications.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.